TAK1 inhibition has shown substantial promise in killing colon and pancreatic cancer cells [35], [36], and data here suggest that TAK1 inhibition, possibly in combination with other therapies, could be effective in preventing LMP1-mediated B cell pathogenesis. The gene discussed is PDLIM7; the disease is pancreatic neoplasm.